Semaglutide Risk: Recent Iowa Study Shows Potential Tumor Growth Risk in Rare Cancers Dave Knapp Sep 9, 2025 3 min read One week, the data says GLP1s might shrink breast tumors
During a two-year follow-up, 5,037 patients taking a GLP-1 developed diabetic retinopathy, compared with 4,938 who were not a 7% increased risk
Common side effects can include nausea, vomiting, diarrhea, constipation, and abdominal pain
A more gradual approach may be recommended if you: Have experienced nausea with GLP-1 medications before Are sensitive to appetite suppressants Have a history of digestive issues Prefer a gentler adjustment period In these cases, remaining on the starting dose longer, or increasing in smaller steps, can significantly improve comfort